Compare CDMOs with metabolic disease manufacturing expertise for GLP-1 agonists, insulin analogs, and oral antidiabetics. Filter by peptide capabilities, dosage form, and scale.
102 companies listed
The metabolic disease space is experiencing unprecedented demand growth, driven by GLP-1 receptor agonists (semaglutide, tirzepatide) for diabetes and obesity. Global GLP-1 manufacturing capacity is severely constrained, with demand outstripping supply by an estimated 2-3x. CDMOs with peptide synthesis, fermentation-based peptide production, and prefilled pen/syringe fill-finish capabilities are the most sought-after partners in pharma.
Peptide manufacturing is the bottleneck. GLP-1 agonists are peptides produced either by solid-phase peptide synthesis (SPPS) or recombinant DNA technology. SPPS is suitable for shorter peptides but faces scale limitations. Recombinant production in E. coli or yeast (Pichia pastoris) enables larger scale but requires fermentation expertise, refolding optimization, and complex purification. CDMOs that can offer both approaches provide sponsors with optionality.
Device integration drives complexity. Most metabolic disease injectables are delivered via pen injectors or autoinjectors for patient self-administration. CDMOs need cartridge filling capability (3mL cartridges for pens), device assembly experience, and combination product regulatory knowledge. The fill-finish step for cartridges requires different equipment and expertise than standard vial filling.
United States
UPM Pharmaceuticals is a U.S.-based CDMO specializing in late-stage commercial manufacturing of semi-solid and oral solid dose products. Operating from a 475,000 sq ft cGMP FDA-registered facility in Bristol, Tennessee, UPM is a family-owned company with 30+ years of experience. They handle DEA-controlled substances and provide services from technology transfer and scale-up through commercial manufacturing. Capabilities include formulation development, analytical development, coated tablet manufacturing, pharmaceutical serialization, aggregation, and full packaging and warehousing.
Japan
PeptiStar is a Japan-based CDMO specializing in the development and cGMP manufacture of peptide and oligonucleotide APIs. From its 10,500 m² R&D and manufacturing site in Settsu, Osaka, the company supports programs from milligram-scale research material through clinical and commercial production. PeptiStar works with complex peptide structures, including long-chain, cyclic, branched and constrained peptides, non-natural amino acids and peptide conjugates. Its route-flexible manufacturing platform includes conventional and microwave-assisted SPPS, STag-PS and SYNCSOL liquid-phase technologies. Integrated downstream capabilities include preparative and continuous chromatography, membrane concentration and lyophilization, with 300 L filter reactors, chromatography columns up to 450 mm and lyophilizers up to 500 L. Purification and subsequent processing are conducted in Class 100,000 controlled areas. PeptiStar also develops and manufactures oligonucleotide APIs and peptide–oligonucleotide conjugates. The company was recognised by Exelixis as its 2025 CDMO of the Year.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.